On Friday, Merck announced positive results on its patent infringement case against Viatris, while Amgen faces political headwinds from the White House.
The company stated that it would start fresh late-stage studies of its HIV treatment, islatravir, months after the U.S. Food and Drug Administration put the trials on hold, citing safety concerns.
Merck veteran Fiona H. Marshall has been tapped as president of the Novartis Institutes for BioMedical Research (NIBR). She takes over from Jay Bradner, who will leave the company effective Oct. 31.
The biopharma industry’s response to the global pandemic has propelled some COVID-19 vaccines into the leading ranks of the world’s best-selling products, with Pfizer/BioNTech’s Comirnaty surpassing AbbVie’s Humira for the No. 1 spot.
The FDA will still allow continued distribution of sitagliptin containing NTTP with an acceptable intake limit of 37 ng per day and up to 246.7 ng per day.
The company’s blockbuster cancer drug, in combination with chemoraditation therapy showed improvement in event-free survival, but the results did not meet statistical significance.
Merck is in late-stage discussions to acquire Seagen for about $40 billion, sources told The Wall Street Journal. Seagen is an appealing oncology target for Merck at a time when the latter is looking to bolster its cancer portfolio as mega-blockbuster Keytruda (pembrolizumab) teeters on the patent cliff.
The values of leading pharmaceutical brands have skyrocketed during the COVID-19 pandemic; Johnson & Johnson retains the top position.
GSK on Tuesday agreed to buy U.S. biotech Affinivax for up to $3.3 billion, its second major deal in two months, giving the British pharmaceutical giant access to the privately held company’s roster of next-generation vaccines.